Biohaven Pharmaceutical Holding (BHVN) Likely to Pre-Release NURTEC-OTD Sales - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating and $177.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
